8:31AM Avanir Pharmaceuticals announces FDA acceptance Of IND For AVP-923 For the treatment of agitation in patients with Alzheimer's Disease (AVNR) 2.90 : Co announced that the FDA accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease. The company plans to initiate a Phase II study evaluating AVP-923 during the third calendar quarter of 2012.